SLRN Live signals | Maximize Profits with Getagraph.com

BUY 120950 min ago

@ $7.58

Issued: 14 Feb 2024 @ 10:18

Return: -36.61%

Previous signal: Feb 13 - 12:30

Previous signal: Sell

Return: -1.69 %

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 11:09):

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines...

Stats
Today's Volume	109 577
Average Volume	1.26M
Market Cap	467.72M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.950
ATR14	$0.0160 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-09	Lin Shao-lee	Buy	964 829	Employee Stock Option (right to buy)
2024-01-09	Lin Shao-lee	Buy	413 498	Employee Stock Option (right to buy)
2024-01-09	Labrucherie Gil M	Buy	855 513	Employee Stock Option (right to buy)
2024-01-02	Lin Shao-lee	Sell	10 691	Common Stock
2023-12-18	Tetrault Lynn A.	Buy	89 955	Director Stock Option (right to buy)

INSIDER POWER
-1.33
Last 57 transactions
Buy: 28 627 675 \| Sell: 30 925 812

Volume Correlation

Long: -0.20 (neutral)

Short: -0.26 (neutral)

Signal:(62.975) Neutral

Acelyrin, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Acelyrin, Inc. Correlation - Currency/Commodity

0.60
( weak )

0.00
( neutral )

0.63
( weak )

0.00
( neutral )

-0.71
( moderate negative )

Acelyrin, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-12.25

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-12.25

Financial Reports:

No articles found.

Acelyrin, Inc.

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Realtime updates for Acelyrin, Inc. [SLRN]

Upcoming Earnings Alert